AUROPHARMA - Aurobindo Pharma

📊 NSE: AUROPHARMA 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/13/2025 18:43

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue grew 6.3% YoY to INR 8,286 Cr in Q2 FY26. US Formulations grew 2% QoQ to USD 417 million (INR 3,634 Cr). Europe Formulations grew 17.8% YoY to INR 2,480 Cr. Growth Markets grew 8.7% YoY to INR 882 Cr. ARV Formulations surged 68.7% YoY to INR 325 Cr. API business declined 16.9% YoY to INR 961 Cr due to market pricing pressures.

Geographic Revenue Split

US Formulations account for 43.9% of consolidated revenue. Europe contributes approximately 30% (INR 2,480 Cr). Growth Markets represent 10.6% (INR 882 Cr). ARV and API segments contribute 3.9% and 11.6% respectively.

Profitability Margins

Gross Margin improved to 59.7% in Q2 FY26 from 58.8% in Q2 FY25 (up 88 bps), driven by favorable raw material prices and business mix. Net Profit Margin for FY25 stood at 11.0%.

EBITDA Margin

EBITDA for Q2 FY26 was INR 1,678 Cr, representing a 20.3% margin (up 16 bps YoY). Excluding gRevlimid, EBITDA grew 14% QoQ, reflecting strong operating leverage and cost efficiency.

Capital Expenditure

Net CapEx for Q2 FY26 was USD 106 million (approx. INR 890 Cr). The company has committed INR 1,000 Cr for the TheraNym mammalian bioreactor facility and is investing in a new vial filling line at CuraTeQ.

Credit Rating & Borrowing

Debt Equity Ratio is low at 0.08 as of March 2025. Average finance costs declined to 4.7% in Q2 FY26 due to effective treasury management. Interest Coverage Ratio stood at 12.2 in FY25.

⚙️ Operational Drivers

Raw Materials

Key inputs include Coal (for power in Pen-G plant), Beta-lactam intermediates (73% of API sales), and Non-Beta lactam intermediates. Specific chemical names are not disclosed in the available documents.

Import Sources

Sourcing includes China (for European supply ramp-up) and domestic Indian markets. Specific state-level sourcing is not disclosed.

Capacity Expansion

Pen-G facility (Lyfius) is ramping up to 15,000 MT capacity. TheraNym is establishing a 2x15 kL mammalian bioreactor facility expected to be ready by June/July 2026. China plant started invoicing in April 2025 with a goal of triple-digit turnover in 3 years.

Raw Material Costs

Raw material costs are optimized through backward integration (Pen-G plant), which is expected to push gross margins above 60% once fully operational. API pricing pressures impacted revenue by 16.9% YoY.

Manufacturing Efficiency

Fixed Asset Turnover was 2.1 in FY25. The company is targeting 100% capacity utilization at the Pen-G plant to reach 15,000 MT production.

📈 Strategic Growth

Expected Growth Rate

20-21%

Growth Strategy

Growth will be driven by the commercialization of the biosimilar portfolio (CuraTeQ), ramp-up of the Pen-G facility, and the Lannett acquisition in the US. The company aims for USD 1 billion in annual revenue from Europe by FY26 through increased in-house supplies and China plant exports.

Products & Services

Oral Solids, Injectables, Biosimilars (Trastuzumab, Bevacizumab, Denosumab, Omalizumab), ARV formulations, and APIs (Beta-lactam and Non-Beta lactam).

Brand Portfolio

Lyfius (Pen-G), CuraTeQ (Biosimilars), TheraNym (Biologics), Lannett (US acquisition).

New Products/Services

Launched 6 new products and filed 13 ANDAs in Q2 FY26. Biosimilars like Trastuzumab and Bevacizumab have received EC and MHRA approvals.

Market Expansion

Expanding in Growth Markets (Indonesia, China, Brazil, Mexico) and scaling the European business to reach a USD 1 billion milestone by FY26.

Strategic Alliances

Signed a second product contract with MSD (Merck) to support expanded scope in biologics, adding two 15 kL bioreactor lines.

🌍 External Factors

Industry Trends

The industry is shifting toward complex generics and biosimilars. Aurobindo is positioning itself through CuraTeQ and TheraNym to capture the biologics CMO and biosimilar market.

Competitive Landscape

Faces competitive pricing pressures in the API and US generic markets.

Competitive Moat

Moat is built on vertical integration (Pen-G backward integration), a diversified global portfolio (US, Europe, Growth Markets), and a robust pipeline of 13 ANDA filings in a single quarter.

Macro Economic Sensitivity

Sensitive to movements in currency exchange and interest rates. The company reported a small FX gain of INR 5 Cr in Q2 FY26 compared to INR 15 Cr YoY.

Consumer Behavior

Increased demand for affordable ARVs and biosimilars globally is driving volume growth.

Geopolitical Risks

Trade barriers and stricter climate regulations pose transition risks and higher compliance costs.

⚖️ Regulatory & Governance

Industry Regulations

Subject to USFDA, European Commission, and MHRA (UK) regulations for product approvals and manufacturing facility inspections.

Environmental Compliance

The company is investing in energy-efficient technologies and conducting energy audits to align with carbon regulations.

Taxation Policy Impact

Reported tax rate is approximately 35% because tax credits are not taken on losses from new businesses (like Pen-G); the effective tax rate on profitable entities is 25%.